This company has been acquired
Valens (VLNS) Stock Overview
The Valens Company Inc., through its subsidiaries, develops, manufactures, and sells cannabinoid-based products in Canada, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
VLNS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Valens Company Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.76 |
| 52 Week High | CA$3.00 |
| 52 Week Low | CA$0.58 |
| Beta | 1.79 |
| 1 Month Change | 15.30% |
| 3 Month Change | 12.87% |
| 1 Year Change | -61.61% |
| 3 Year Change | -91.13% |
| 5 Year Change | -87.39% |
| Change since IPO | -72.44% |
Recent News & Updates
The Valens Q3 Earnings Preview
The Valens (NASDAQ:VLNS) is scheduled to announce Q3 earnings results on Thursday, October 13th, before market open. The consensus Revenue Estimate is $20.68M (-1.5% Y/Y).SNDL to acquire rival cannabis player Valens in all stock deal
SNDL (SNDL) announced Monday that the Canadian cannabis company inked an agreement to acquire the domestic rival The Valens Company (NASDAQ:VLNS) for nearly $138M in an all-stock deal. SNDL is currently trading sharply lower while VLNS is on hold for trading. Per the terms, SNDL will buy all VLNS common shares other than it already owns in exchange for 0.3334 of SNDL common share for each VLNS share, and VLNS investors will own ~9.5% of the pro forma entity. The consideration implies $1.26 per VLNS share and indicates a premium of 10% based on the stock’s trailing 30-day volume-weighted average price. The combined entity will be a vertically integrated cannabis platform and operate as SNDL Inc. The transaction is expected to close in Jan. 2023.The Valens GAAP EPS of -$2.13, revenue of $24M beats by $4.55M
The Valens press release (NASDAQ:VLNS): Q2 GAAP EPS of -$2.13. Revenue of $24M (+3.5% Y/Y) beats by $4.55M. Adjusted gross profit was $3.4 million, or 14.0% of net revenue in Q2 2022, compared to $3.4 million, or 14.6% of net revenue, in Q1 2022. Adjusted EBITDA was $(15.9) million, in Q2 2022 compared to $(17.6) million in Q1 2022. Valens expects Q3 2022 cash flow from operations between $(9) million to $(12.5) million.Recent updates
Shareholder Returns
| VLNS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.03% | 2.7% | -2.4% |
| 1Y | -61.6% | 38.2% | 21.5% |
Return vs Industry: VLNS underperformed the US Pharmaceuticals industry which returned -3.7% over the past year.
Return vs Market: VLNS underperformed the US Market which returned 14.1% over the past year.
Price Volatility
| VLNS volatility | |
|---|---|
| VLNS Average Weekly Movement | 10.3% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VLNS's share price has been volatile over the past 3 months.
Volatility Over Time: VLNS's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 445 | n/a | www.thevalenscompany.com |
The Valens Company Inc., through its subsidiaries, develops, manufactures, and sells cannabinoid-based products in Canada, the United States, and internationally. The company provides packaged dried flower/pre-rolls under the Verse, Versus, Contraband, and Citizen Stash brands; vapourizers and hydrocarbon extracts under the Verse and Versus brands; edible cannabis products under the Verse, Vacay, and LYF brands; and topical cannabis under the Nuance brand. It also offers analytical testing services to third party licensed producers in the cannabis space.
The Valens Company Inc. Fundamentals Summary
| VLNS fundamental statistics | |
|---|---|
| Market cap | US$60.49m |
| Earnings (TTM) | -US$174.46m |
| Revenue (TTM) | US$63.62m |
Is VLNS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VLNS income statement (TTM) | |
|---|---|
| Revenue | CA$85.89m |
| Cost of Revenue | CA$88.93m |
| Gross Profit | -CA$3.03m |
| Other Expenses | CA$232.49m |
| Earnings | -CA$235.52m |
Last Reported Earnings
Aug 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.91 |
| Gross Margin | -3.53% |
| Net Profit Margin | -274.21% |
| Debt/Equity Ratio | 75.7% |
How did VLNS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/01/19 20:16 |
| End of Day Share Price | 2023/01/18 00:00 |
| Earnings | 2022/08/31 |
| Annual Earnings | 2021/11/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
The Valens Company Inc. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Kideckel | ATB Cormark |
| Kimberly Thompson-Hedlin | Canaccord Genuity |
| John Chu | Desjardins Securities Inc. |